Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Japan’s Itochu Biologic Subsidiary To Launch First Drug In Taiwan

This article was originally published in PharmAsia News

Executive Summary

Japanese major trading house Itochu's bioventure subsidiary, Tokyo-based Solasia Pharma K.K., plans to launch its first drug to the Taiwanese market within the year. The drug, Sancuso (transdermal granisetron) patch is for chemotherapy-induced nausea and vomiting. Solasia also is preparing to launch the drug in China and other Asian markets. Compared to current oral therapy, the Sancuso patch allows patients with swallowing difficulties to use it. The company aims for ¥8 billion in annual sales by 2015. (Click here for more - Japanese language

Table

View full table

Tags:
Latest Headlines

Executives On The Move: Senior Moves At Innovent Biologics, Actym Therapeutics And Enanta Pharmaceuticals

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

See All
UsernamePublicRestriction

Register

SC071553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By